Coherus Oncology (CHRS) Q4 2025 earnings review
Transformation Complete: Clean Balance Sheet, Growing Sales, and a High-Stakes Pipeline
Coherus closes the book on 2025 having successfully executed one of the most drastic corporate pivots in the biotech sector. Exiting its legacy biosimilars business allowed the company to slash its massive debt load by over 90% and rebrand as a pure-play innovative oncology firm. Financially, the newly minted 'Coherus Oncology' is stabilizing: LOQTORZI, its foundational PD-1 inhibitor, posted steady double-digit sequential growth, bringing full-year sales to $40.8 million. However, the future hinges entirely on the clinical pipeline—specifically, its anti-CCR8 and anti-IL-27 antibodies. With R&D expenses accelerating and critical data readouts not due until mid-to-late 2026, the company successfully bought itself runway, but the real test of its scientific thesis is just beginning.
🐂 Bull Case
By divesting UDENYCA, CIMERLI, and YUSIMRY, Coherus eliminated a crippling debt overhang. Debt plummeted from $480 million to just $38.8 million, drastically reducing interest expense and removing existential financing risks.
The company's foundational commercial asset grew 64% YoY in Q4. It's successfully penetrating academic centers as the NCCN's preferred treatment for nasopharyngeal carcinoma, providing a growing baseline of non-dilutive funding.
🐻 Bear Case
The company’s valuation is now inextricably tied to Phase 1/2 readouts for tagmokitug and casdozokitug expected in mid-to-late 2026. A failure in these highly competitive spaces (especially CCR8) would devastate the investment thesis.
Reaching LOQTORZI's $150-$200M peak sales target requires changing entrenched prescribing habits among community oncologists, who are accustomed to using KEYTRUDA off-label. This is a slow, expensive educational grind.
⚖️ Verdict: ⚪
Neutral. The financial engineering and strategic pivot were executed flawlessly, saving the company from a debt spiral. However, investors are now holding a clinical-stage biotech dependent on unproven mechanisms of action. The recent $47M equity raise hints that cash burn remains a real concern ahead of 2026 catalysts.
Key Themes
Debt Obliteration Unlocks Strategic Flexibility
The defining achievement of 2025 was the aggressive deleveraging of the balance sheet. Following the UDENYCA divestiture, management wiped out the massive $230M convertible notes and paid off legacy term loans. This reversing trend in debt (down to $38.8M) has lowered quarterly interest expense to just $2.2M, buying the company the strategic flexibility needed to focus entirely on its clinical pipeline.
LOQTORZI as a Differentiated Combination Backbone
LOQTORZI's value extends far beyond its current NPC indication. Management is positioning it as a highly potent, proprietary PD-1 inhibitor to serve as the backbone for combination therapies across the entire pipeline. By owning global rights to both the PD-1 and the novel agents (casdozokitug and tagmokitug), Coherus secures immense operational and pricing advantages compared to biotechs forced to purchase KEYTRUDA or OPDIVO for combination trials.
Opex Divergence: R&D Accelerates while SG&A Compresses
A clear structural shift is visible in the income statement. Driven by lower headcount post-biosimilar divestiture, SG&A is steadily decelerating. Conversely, R&D expenses are accelerating sharply as Coherus ramps up multiple dose optimization and expansion cohorts for its pipeline assets. This is the textbook financial profile of an innovative oncology company.
Tagmokitug (anti-CCR8) Emerges as Lead Clinical Asset
The highly selective anti-CCR8 antibody, previously known as CHS-114, has been named tagmokitug. Recent publications validate its mechanism: specifically binding and eliminating CCR8+ tumor regulatory T cells (Tregs) without off-target binding. Clinical momentum is accelerating with trials underway in HNSCC, upper GI, ESCC, and colorectal cancer, creating multiple shots on goal for this potentially best-in-class asset.
Headline Cash Obscures Actual Liquidity
Management touted a robust $172.1M in year-end cash, cash equivalents, and marketable securities. However, this figure is artificially inflated. The balance includes $65.1M in Transition Service Agreement (TSA)-related collections that are strictly earmarked to be applied against associated TSA payables. Stripping this out, 'clean' liquidity is closer to $107M, highlighting why the company had to execute a $47M public offering in February 2026.
Community Oncology Inertia (Industry Headwind)
Despite pristine clinical data and top-tier NCCN guideline placement, Coherus faces a massive structural headwind in the community oncology setting. Because nasopharyngeal carcinoma is rare, community doctors see very few cases and default to off-label use of legacy IO agents out of habit. Breaking this inertia requires disproportionate commercial effort and limits the speed of LOQTORZI's growth.
Intensifying Cash Burn from Clinical Expansion
R&D expenses jumped nearly 50% YoY in Q4 to $31.0M. As the company advances casdozokitug in a randomized Phase 2 trial and pushes tagmokitug into multiple cohorts—plus a newly announced combination with J&J's pasritamig in prostate cancer—clinical trial costs will continue to compound. The race between LOQTORZI's revenue ramp and clinical cash burn will be extremely tight.
Other KPIs
Stable. Cost of goods sold for Q4 2025 was $4.0M against $12.7M in total continuing operations revenue. This yields a strong ~68% gross margin, which is standard for commercialized biologics and indicates healthy profitability on the product itself as volumes scale.
This massive windfall formally marks the exit from the biosimilars space (primarily the UDENYCA divestiture). It heavily skewed the full-year GAAP Net Income to a positive $168.0M, though investors must recognize this is entirely a one-time structural event.
Guidance
Stable. Initial data readouts for these critical dose-optimization studies remain on track. This will be the first major test to see if the preclinical Treg depletion translates into competitive overall response rates against standard of care.
Stable. First data from the randomized Phase 2 trial. The prior triplet study showed an impressive 38% ORR and 17% Complete Response rate. The market will heavily scrutinize whether this mid-2026 data can replicate or exceed those numbers.
Key Questions
R&D Run-Rate Expectations
With R&D stepping up significantly to $31M in Q4, and multiple new cohorts (including mCRPC) launching, what is the expected normalized quarterly R&D run rate for 2026?
Cash Runway Clarification
Given the $65M in TSA encumbrances on the balance sheet, how far into 2026 or 2027 does the recently completed $47M February equity raise actually extend the company's operational runway?
Partnership Economics
Management has frequently discussed securing ex-U.S. licensing deals for the pipeline to generate non-dilutive capital. Is the company requiring mid-2026 data readouts to finalize these deals, or are active negotiations advancing based on current data?